Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
about
Methylphenidate enhances NMDA-receptor response in medial prefrontal cortex via sigma-1 receptor: a novel mechanism for methylphenidate actionThe Potential for Misuse and Abuse of Medications in ADHD: A ReviewLong-Term Outcomes with Medications for Attention-Deficit Hyperactivity DisorderAmphetamine, past and present--a pharmacological and clinical perspectiveFuture pharmacological treatments for substance use disordersAddiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulantsCognitive enhancers for the treatment of ADHDThe cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortexPsychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorderSelective noradrenaline reuptake inhibitors for schizophreniaAtomoxetine for schizophreniaPharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disordersPharmacological treatment for attention deficit hyperactivity disorder in children with co-morbid tic disordersInfluence of methylphenidate on brain development--an update of recent animal experiments.Norepinephrine transporter inhibitors and their therapeutic potentialSingle-action versus dual-action antidepressantsThe neuropsychopharmacology of fronto-executive function: monoaminergic modulationThe use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorderNeuropharmacological mechanisms underlying the neuroprotective effects of methylphenidateAcute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2C) receptor antagonist.Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder.Animal models of attention-deficit hyperactivity disorder.Catecholamines and cognition after traumatic brain injuryEffect of Pharmacological Interventions on the Fronto-Cingulo-Parietal Cognitive Control Network in Psychiatric Disorders: A Transdiagnostic Systematic Review of fMRI StudiesTrace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical ImplicationsSex Differences in Behavioral Dyscontrol: Role in Drug Addiction and Novel TreatmentsA review of atomoxetine effects in young people with developmental disabilitiesAdvances in molecular genetic studies of attention deficit hyperactivity disorder in ChinaReducing substance use during adolescence: a translational framework for preventionA brief history of the development of antidepressant drugs: from monoamines to glutamateBrinp1(-/-) mice exhibit autism-like behaviour, altered memory, hyperactivity and increased parvalbumin-positive cortical interneuron densityPharmacotherapy for attention-deficit/hyperactivity disorder: from cells to circuits.Metabotropic glutamate receptor dependent long-term depression in the cortexFrom Clinical Application to Cognitive Enhancement: The Example of MethylphenidateEffects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activityAtomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patientsAtomoxetine, a novel treatment for attention-deficit-hyperactivity disorderTipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary studyNeuropharmacological effect of methylphenidate on attention network in children with attention deficit hyperactivity disorder during oddball paradigms as assessed using functional near-infrared spectroscopyNeuropharmacological effect of atomoxetine on attention network in children with attention deficit hyperactivity disorder during oddball paradigms as assessed using functional near-infrared spectroscopy
P2860
Q21090824-826023F9-C320-4C98-AB17-0073A0FA3BA1Q22241206-71E0727F-3B84-49F0-9A1A-9797E02D1F70Q22241421-B6D4345A-FA50-4985-98EF-9E43CE80DB8EQ22241826-B48B262A-8962-4E5E-AF74-A84681E5182FQ22242633-1087AD78-B8B2-42FF-AB85-0059673F8D4FQ22251215-CB7B13BA-8769-45C1-9AEE-29F1C7C63699Q22251235-54DFE528-7B91-4E06-A1F7-3D57A088138AQ22252343-F1DD3665-5F88-4F47-8BE1-3B59BB2F86E0Q22252504-178A1C60-0F65-40EF-835D-D9113CDDC9E3Q24197825-91CED454-AAA6-4F4A-B499-0E9D74807263Q24198212-0C836864-DEBF-4C7B-A99E-6276891DDF13Q24235048-8FB03EBF-2F98-4865-ADAC-93662A0A6B8CQ24240859-3B473AD2-9B6B-429E-B1AF-09A055694251Q24537917-1B08B0E0-14F5-4E3D-9D25-2CDC5F65AEA6Q24554381-72033C64-D7AE-41AF-9DF7-D7A55745AD57Q24562551-8264B6DB-6CED-471A-9AF1-D672E92127B0Q24629562-23909490-289F-4704-AC40-8332334940D8Q24629736-08D0026C-0B21-4799-B7F6-A4E23270445EQ24658233-D978E0EC-C14D-4C85-BCA2-98B6E79D87ECQ24684698-C163BDDA-C99F-463D-BCE0-9FEDD1514046Q24810310-3C167B7E-B7CD-4491-98B4-361D02C6DE9CQ24814868-C3F3E2D2-088A-4F90-BDD9-0F3B28354CE9Q26743582-3381886B-438B-4519-8B12-4C41EC4E15E3Q26744718-0A3CE4D2-59B2-4590-AFE0-6D4B1E009915Q26752602-FF26D38F-5BA1-4BBB-8EDA-BEEA749F06FEQ26768148-27EB7501-EA9C-4623-911B-55187430140DQ26863679-2F5BD040-D90E-4B8E-A7E5-DE66606426CAQ26995422-270984CB-5665-4FEC-88B4-60B83B976B35Q27023852-EA99E2A9-8C34-4EF6-8FFD-F15FAF53B515Q27028050-1CF81494-F4D0-452F-8E47-BD73B37F70A4Q27322895-A72F222E-B6A4-4A55-93D8-0DBEDAB7DD61Q27687469-667E0D0A-EFCE-4569-989D-04BDFFD12854Q28067869-4ED02EC0-B1B3-443F-AA1A-145AAD3387F9Q28073785-2D042A8E-C605-4205-AFD9-E2178911E56DQ28256557-96E0F9E5-A13B-4842-893F-7FF16E48A671Q28267079-72976B29-6EFC-41E5-B482-CAAC1DCECA9CQ28279863-F49B75A4-D0FB-4AB7-AF8F-A39EABC24503Q28307232-7E6D5E0C-297B-4974-B189-4464F928FB67Q28647972-B82BBCF8-5ACA-4F1C-9140-53C48C9605F9Q28647973-44B3B76E-3A26-46B6-9DF8-6AE432EF9296
P2860
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Atomoxetine increases extracel ...... eficit/hyperactivity disorder.
@ast
Atomoxetine increases extracel ...... eficit/hyperactivity disorder.
@en
Atomoxetine increases extracel ...... eficit/hyperactivity disorder.
@nl
type
label
Atomoxetine increases extracel ...... eficit/hyperactivity disorder.
@ast
Atomoxetine increases extracel ...... eficit/hyperactivity disorder.
@en
Atomoxetine increases extracel ...... eficit/hyperactivity disorder.
@nl
prefLabel
Atomoxetine increases extracel ...... eficit/hyperactivity disorder.
@ast
Atomoxetine increases extracel ...... eficit/hyperactivity disorder.
@en
Atomoxetine increases extracel ...... eficit/hyperactivity disorder.
@nl
P2093
P921
P1476
Atomoxetine increases extracel ...... eficit/hyperactivity disorder.
@en
P2093
David L Nelson
Donald R Gehlert
Frank P Bymaster
Jason S Katner
John H Heiligenstein
Kenneth W Perry
Penny G Threlkeld
S Michelle Morin
Susan K Hemrick-Luecke
P304
P356
10.1016/S0893-133X(02)00346-9
P407
P577
2002-11-01T00:00:00Z
P6179
1003356280